K. Fenwick

发表

Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation

A. Ashworth, M. Zvelebil, N. Orr, 2012, Nucleic acids research.

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis

A. Ashworth, J. Reis-Filho, C. Botta, 2009, The Journal of pathology.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines

A. Ashworth, W. Foulkes, J. Reis-Filho, 2011, BMC Medical Genomics.

Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C

A. Ashworth, N. Orr, O. Fletcher, 2014, Genome research.

Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen

A. Ashworth, M. Zvelebil, I. Kozarewa, 2011, Proceedings of the National Academy of Sciences.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

M. Dowsett, S. Chandarlapaty, I. Smith, 2015, Science Translational Medicine.

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

A. Ashworth, G. Morgan, N. Potter, 2012, Blood.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Alan Ashworth, James Campbell, Kerry Fenwick, 2014, Cancer research.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Sue Chua, Alex Pearson, James Campbell, 2016, Cancer discovery.

Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components

A. Ashworth, I. Ellis, J. Reis-Filho, 2009, The Journal of pathology.

The genomic profile of HER2‐amplified breast cancers: the influence of ER status

A. Ashworth, J. Reis-Filho, A. Sapino, 2008, The Journal of pathology.

Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast

A. Ashworth, J. Reis-Filho, A. Sapino, 2008, The Journal of pathology.

Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.

A. Ashworth, J. Reis-Filho, Chris Jones, 2006, Genomics.

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity

A. Ashworth, S. Lakhani, J. Reis-Filho, 2005, The Journal of pathology.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

Alan Mackay, Chris Jones, Alan Ashworth, 2008, Laboratory Investigation.

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

K Fenwick, A. Ashworth, T. Powles, 2006, British Journal of Cancer.

FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

Alan Mackay, Chris Jones, Alan Ashworth, 2006, Clinical Cancer Research.

Capture Hi-C identifies putative target genes at 33 breast cancer risk loci

Frank Dudbridge, Nick Orr, Olivia Fletcher, 2018, Nature Communications.

Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication

Robin L. Jones, A. Ashworth, J. Reis-Filho, 2009, Journal of Clinical Pathology.

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas

A. Ashworth, J. Reis-Filho, A. Longatto-Filho, 2009, British Journal of Cancer.

Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer

G. Sauter, M. Gerlinger, A. Marx, 2019, Nature Communications.

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease

R. Eeles, Z. Kote-Jarai, M. Guy, 2014, British Journal of Cancer.

Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation

Alan Mackay, Chris Jones, Alan Ashworth, 2007, Laboratory Investigation.

Hemangioendothelioma Identification of a Disease-Defining Gene Fusion in Epithelioid

M. Gerstein, R. West, A. Ashworth, 2011 .

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment

A. Rust, J. Yarnold, K. Fenwick, 2018, Breast Cancer Research and Treatment.

An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.

Marketa Zvelebil, Stuart M Haslam, Anne Dell, 2014, Cancer discovery.

Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells

A. Ashworth, J. Reis-Filho, Chris Jones, 2006, Journal of Clinical Pathology.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

A. Ashworth, H. Gevensleben, N. Tunariu, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour

A. Ashworth, J. Reis-Filho, R. Natrajan, 2007, The Journal of pathology.

A method for resequencing from minimal amounts of starting DNA.

A. Ashworth, M. Zvelebil, I. Kozarewa, 2012 .

The genomic landscape of oesophagogastric junctional adenocarcinoma

A. Ashworth, N. Orr, A. Wotherspoon, 2013, The Journal of pathology.

Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer

M. Gerlinger, T. Lund, K. Fenwick, 2022, bioRxiv.

Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor

Robert Karlsson, Julian Peto, Fredrik Wiklund, 2017, Nature Genetics.

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress

A. Ashworth, N. Orr, S. McDade, 2014, Nucleic acids research.

Molecular response to aromatase inhibitor treatment in primary breast cancer

A. Ashworth, M. Dowsett, A. Urruticoechea, 2007, Breast Cancer Research.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

A. Ashworth, E. Swisher, S. Pettitt, 2017, bioRxiv.

Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine‐tiling oligonucleotide array CGH

A. Ashworth, A. Grigoriadis, R. Williams, 2007, Genes, chromosomes & cancer.

Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas

A. Ashworth, S. Lakhani, J. Reis-Filho, 2008, The Journal of pathology.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast

A. Ashworth, A. Chinnaiyan, C. Maher, 2014, The Journal of pathology.

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

I. Kozarewa, K. Fenwick, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

Elizabeth Iorns, Jorge S. Reis-Filho, Alan Ashworth, 2009, PloS one.

Whole‐exome DNA sequence analysis of Brca2‐ and Trp53‐deficient mouse mammary gland tumours

A. Ashworth, I. Kozarewa, K. Fenwick, 2015, The Journal of pathology.

Array CGH of fusion gene–positive leukemia‐derived cell lines reveals cryptic regions of genomic gain and loss

A. Ashworth, L. Kearney, K. Fenwick, 2006, Genes, chromosomes & cancer.

susceptibility loci by Capture HiC Unbiased analysis of potential targets of breast cancer

A. Ashworth, N. Orr, O. Fletcher, 2014 .

Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma

M. Gerstein, R. West, A. Ashworth, 2011, Science Translational Medicine.

Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer

A. Ashworth, M. Zvelebil, I. Kozarewa, 2011, PloS one.

Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse

K Fenwick, A. Ashworth, O. Dovey, 2006, The Journal of pathology.

Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation

A. Ashworth, G. Morgan, Chris Jones, 2008, Leukemia & lymphoma.

Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor

A. Ashworth, James R. Anderson, T. Chagtai, 2011, Genes, chromosomes & cancer.

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

A. Ashworth, J. Reis-Filho, I. Kozarewa, 2013, The Journal of pathology.

High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing

Marketa Zvelebil, Alan Ashworth, Costas Mitsopoulos, 2011, Genome Biology.

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

A. Ashworth, A. Oza, M. Gore, 2013, Clinical Cancer Research.

PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

Marketa Zvelebil, Alan Mackay, Alan Ashworth, 2009, Clinical Cancer Research.

Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH

A. Ashworth, B. Weber, A. Freeman, 2005, Prostate Cancer and Prostatic Diseases.

Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas

A. Ashworth, J. Reis-Filho, M. Gore, 2011, Clinical Cancer Research.

Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma

K. von Loga, M. Hubank, R. Natrajan, 2021, Cancers.

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers

A. Rust, N. Matthews, M. Hubank, 2018, The journal of pathology. Clinical research.

Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy

A. Camargo, M. Gerlinger, Dimitrios Kleftogiannis, 2020, Cancers.

Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

C. V. Jongeneel, Christian Iseli, Brian J. Stevenson, 2006, Breast Cancer Research.

Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

A. Ashworth, A. Tutt, J. Reis-Filho, 2009, Clinical Cancer Research.

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor

A. Ashworth, M. Zvelebil, Dafydd G. Thomas, 2012, Breast Cancer Research and Treatment.

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

S. Loi, S. Loibl, F. André, 2018, Cancer discovery.

Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors

A. Ashworth, J. Reis-Filho, N. Sebire, 2008, Clinical Cancer Research.

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

A. Ashworth, J. Reis-Filho, A. Grigoriadis, 2009, Breast Cancer Research and Treatment.

Genomic characterisation of acral melanoma cell lines

A. Ashworth, M. Zvelebil, J. Reis-Filho, 2012, Pigment cell & melanoma research.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

J. Downward, I. Kozarewa, K. Fenwick, 2015, PloS one.

Genome‐wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c‐Kit, CD117) and oestrogen receptor‐α (ERα) in response to therapeutic radiation

A. Ashworth, J. Reis-Filho, C. Isacke, 2009, The Journal of pathology.

Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma

Alan Mackay, Narinder Tamber, Alan Ashworth, 2009, Histopathology.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

M. Gerlinger, M. Davies, B. Herman, 2018, Clinical chemistry.

A Modified Method for Whole Exome Resequencing from Minimal Amounts of Starting DNA

A. Ashworth, M. Zvelebil, G. Morgan, 2012, PloS one.

PO-457 Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers

R. Natrajan, K. Fenwick, F. Daley, 2018, ESMO Open.

Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers

A. Ashworth, A. Grigoriadis, K. Fenwick, 2007, Breast Cancer Research.

A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

A. Ashworth, S. Pettitt, I. Kozarewa, 2013, PloS one.

The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing

A. Rust, A. Wotherspoon, D. Cunningham, 2021, Journal of clinical medicine.

Ultra-sensitive mutation detection and genome-wide DNA copy 11 number reconstruction by error corrected circulating tumor DNA 12 sequencing 13 14

M. Davies, B. Herman, M. Hubank, 2018 .

Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC)

S. Bhide, K. Harrington, K. Fenwick, 2020, Frontiers in Oncology.

Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.

S. Loi, S. Loibl, F. André, 2018 .